Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd. (PPBT) generates frequent news as a clinical-stage oncology company developing therapies that, according to its own reports, target tumor immune evasion and drug resistance. Investors and observers following PPBT news can track updates on its CAPTN-3 tri-specific antibody platform, the CEACAM1-blocking antibody CM24, and the dual IRS1/2 and STAT3 inhibitor NT219, as well as financing and listing developments.
Recent press releases highlight CAPTN-3 as a key source of news. The company has announced manufacturing milestones for IM1240, the first tri-specific antibody from the platform targeting 5T4, CD3 and NKG2A, including achievement of a commercially viable yield. Additional updates describe non-human primate toxicology data for IM1240, with Purple Biotech reporting an expanded therapeutic window compared with a non-capped comparator and a pharmacokinetic profile characterized by increased systemic exposure and prolonged half-life in that study.
News flow also covers preclinical data presentations at scientific meetings such as the ESMO Immuno-Oncology Congress and other conferences. These releases describe anti-tumor activity of IM1240 and IM1305 in models resistant to prior PD-1 therapy, transcriptomic analyses supporting the inclusion of an NKG2A arm, and ex vivo results in patient-derived tumor biopsies. Such items provide context on how the company positions CAPTN-3 within immuno-oncology research.
Beyond CAPTN-3, Purple Biotech issues updates on CM24 Phase 2 data in pancreatic ductal adenocarcinoma and on NT219, including an intention to grant a European patent for NT219 combination regimens and progress of a Phase 2 study in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Financial and corporate news includes quarterly results, public offerings of American Depositary Shares and warrants, at-the-market offering agreements, and Nasdaq minimum bid price notifications.
Readers who monitor PPBT news can use this page to follow scientific milestones, regulatory and clinical progress, capital-raising transactions, and listing-related announcements directly sourced from company press releases and SEC-furnished documents.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) recently inaugurated its Scientific Advisory Board (SAB), comprised of three experts from oncology and cancer research. This initiative aims to enhance the company's strategic direction in developing innovative cancer therapies targeting tumor immune evasion and drug resistance. The SAB includes distinguished members: Eyal Gottlieb, PhD, from MD Anderson; Steven Maron, MD, from Memorial Sloan Kettering; and Sunil Sharma, MD, MBA, from Translational Genomics. The board will assist management by providing scientific guidance on clinical trials and R&D activities, which is expected to aid in the advancement of the company’s oncology pipeline, including therapies like NT219 and CM24.
Purple Biotech (NASDAQ/TASE: PPBT) has unveiled promising preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2023, held on April 18, 2023. The results highlight the effectiveness of NT219, a novel small molecule dual inhibitor targeting IRS1/2 and STAT3, in enhancing immune responses in the tumor microenvironment (TME).
Key findings include:
- NT219 significantly increased PDL1 expression in resistant melanoma cells and enhanced anti-PD1 therapy effectiveness.
- In combination with anti-PD1 or anti-CTLA4, NT219 drove significant increases in activated CD8 cytotoxic T and NK cells while decreasing immunosuppressive cell populations.
- NT219 showed lasting effects on IRS1 and STAT3 phosphorylation, linked to tumor drug resistance.
The results indicate NT219 could convert resistant tumors into responders for immune checkpoint blockade therapies.
Purple Biotech (NASDAQ/TASE: PPBT) announced the participation of Dr. Amir Horowitz at Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference on April 20, 2023. He will present on the newly acquired Tri-specific antibody as part of the panel titled New & better Approaches for Oncology Targets. The presentation will take place from 2:00-2:45 PM ET, and a live webcast will be accessible to registered attendees.
Purple Biotech is a clinical-stage company focused on therapies that combat tumor immune evasion and drug resistance. Its oncology pipeline includes NT219, CM24, and IM1240, addressing various solid tumors. The ongoing studies involve NT219, which targets IRS1/2 and STAT3, and CM24, a monoclonal antibody in collaboration with Bristol Myers Squibb.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) announced that CEO Gil Efron is on medical leave due to an accident, with Isaac Israel appointed as acting CEO. The company emphasizes that its business plan and clinical development programs will proceed as scheduled. The announcement reassures stakeholders about continuity and stability during this transition. Purple Biotech focuses on developing therapies that tackle tumor immune evasion and drug resistance, with a pipeline including NT219 and CM24 in various clinical stages. The company remains committed to its 2023 objectives despite the leadership change.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) announced results from a Phase 1 dose escalation study involving CM24 plus nivolumab, indicating promising potential in treating advanced cancers. The trial enrolled 14 patients, primarily with pancreatic adenocarcinoma, showing durable reductions in serum myeloperoxidase, a NETs biomarker. Higher CEACAM1+ lymphocyte levels correlated with improved survival rates. This study supports a biomarker-driven strategy for patient selection. CM24, a novel monoclonal antibody, targets immune evasion pathways, and is being evaluated in a Phase 2 study for metastatic pancreatic cancer. Further results will be shared at an upcoming conference.